✦ LIBER ✦

Long-term outcomes in the second-line treatment of chronic myeloid leukemia : A review of tyrosine kinase inhibitors

✍ Scribed by Elias Jabbour; Jorge Cortes; Hagop Kantarjian

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 156 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25656

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early cytogenetic and molecular response

Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase : Long-term implications

✍ Alfonso Quintás-Cardama; Jorgé E. Cortes; Hagop M. Kantarjian 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Complexity of BCR-ABL kinase domain muta

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

✍ Dushyant Verma; Carmen Fava; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

The effect of interleukin 11 on thromboc

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Ahmed Aribi; Hagop Kantarjian; Charles Koller; Deborah Thomas; Stefan Faderl; Gu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

Significance of suboptimal response to i

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 1 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during

Prediction of successful outcome in a ra

Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C

✍ Vandelli, Carmen; Renzo, Francesco; Braun, Hans Bertram; Tisminetzky, Sergio; Al 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

To evaluate the efficacy of a 12-month course of recombinant interferon alpha (IFN-␣2b), and to assess predictive factors of successful response to IFN therapy in chronic active hepatitis C (HCV CAH), 242 patients with histologically proven HCV CAH were assigned randomly to two groups, one treated w